ScholarIQanswers from OpenAlex & ORCID
Peter A. Fasching
ResearcherPublications, citations & collaboration network
Peter A. Fasching is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Peter A. Fasching have?
ScholarIQindexed works
Peter A. Fasching has 2,039 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Peter A. Fasching have?
ScholarIQcitation count
Peter A. Fasching has 81,246 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Peter A. Fasching?
ScholarIQh-index
Peter A. Fasching has an h-index of 123 in OpenAlex.
What is the i10-index of Peter A. Fasching?
ScholarIQi10-index
Peter A. Fasching has an i10-index of 715 in OpenAlex.
What is the ORCID of Peter A. Fasching?
ScholarIQorcid
The ORCID for Peter A. Fasching is on the source record.
What is the OpenAlex record for Peter A. Fasching?
ScholarIQopenalex
The OpenAlex for Peter A. Fasching is on the source record.
What are the most-cited papers on Peter A. Fasching?
ScholarIQmost cited works
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P. Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa, Sandra M. Swain, Tatiana M. Prowell, Sibylle Loibl, D. Lawrence Wickerham, Jan Bogaerts, José Baselga, Charles M. Perou, Gideon M. Blumenthal, Jens‐Uwe Blohmer, Eleftherios P. Mamounas, Jonas Bergh, Semiglazov Vf, Robert Justice, Holger Eidtmann, Soonmyung Paik, Martine Piccart, Rajeshwari Sridhara, Peter A. Fasching, Leen Slaets, Shenghui Tang, Bernd Gerber, Charles E. Geyer, Richard Pazdur, Nina Ditsch, Priya Rastogi, W. Eiermann, Gϋnter von Minckwitz
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid, Javier Cortés, Lajos Pusztai, Heather L. McArthur, Sherko Kümmel, Jonas Bergh, Carsten Denkert, Yeon Hee Park, Rina Hui, Nadia Harbeck, Masato Takahashi, Theodoros Foukakis, Peter A. Fasching, Fátima Cardoso, Michael Untch, Liyi Jia, Vassiliki Karantza, Jing Zhao, Gursel Aktan, Rebecca Dent, Joyce O’Shaughnessy
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
Gϋnter von Minckwitz, Michael Untch, Jens‐Uwe Blohmer, Serban Dan Costa, Holger Eidtmann, Peter A. Fasching, Bernd Gerber, W. Eiermann, J. Hilfrich, Jens Huober, Christian Jackisch, Manfred Kaufmann, Gottfried E. Konecny, Carsten Denkert, Valentina Nekljudova, Keyur Mehta, Sibylle Loibl
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
Gϋnter von Minckwitz, Chiun‐Sheng Huang, Max S. Mano, Sibylle Loibl, Eleftherios P. Mamounas, Michael Untch, Norman Wolmark, Priya Rastogi, Andreas Schneeweiß, Andrés Redondo, Hans Holger Fischer, William Jacot, Alison Conlin, Claudia Arce-Salinas, Irene Wapnir, Christian Jackisch, Michael P. DiGiovanna, Peter A. Fasching, John Crown, P Wülfing, Zhimin Shao, Elena Rota Caremoli, Haiyan Wu, Lisa H. Lam, David Tesarowski, Melanie C. Smitt, Hannah Douthwaite, Stina Mui Singel, Charles E. Geyer
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert, Gϋnter von Minckwitz, Silvia Darb‐Esfahani, Bianca Lederer, Barbara Ingold Heppner, Karsten E. Weber, Jan Budczies, Jens Huober, Frederick Klauschen, Jenny Furlanetto, Wolfgang Schmitt, Jens‐Uwe Blohmer, Thomas Karn, Berit M. Pfitzner, Sherko Kümmel, Knut Engels, Andreas Schneeweiß, Arndt Hartmann, Aurelia Noske, Peter A. Fasching, Christian Jackisch, Marion van Mackelenbergh, Hans‐Peter Sinn, Christian Schem, Claus Hanusch, Michael Untch, Sibylle Loibl